

NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG COMMITTEE

DISEASE SITE COMMITTEE MEETING
OPEN AGENDA

Friday, April 28, 2006 ~ 13.30 – 16.30
Room: Mont Royal/Hampstead

Chair: Gerald Batist

1:30 p.m. Welcome

TRIAL REPORTS

IND.152	Phase II	PS-341 Waldenstrom's	E. Eisenhauer
IND.160	Phase II	CCI-779 Endometrium	A Oza
IND.167	Phase II	Bay 43-9006 Prostate	K Chi
IND.171	Phase I (NSCLC portion):	AZD2171 + carboplatin/paclitaxel	S Laurie

2:00 p.m. **EDUCATIONAL SESSIONS (15' COFFEE BREAK MID AFTERNOON)**
(15') Report from Health Canada

Dr. C. Nestruck
Health Canada

(20') Oncolytic Viruses as Cancer Therapeutics

J. Bell
Ottawa Hospital Research Institute

(20') Early Development of Targeted Anti-cancer Agents: Endpoints and Designs
Cancer Therapy Evaluation Program, NCI Bethesda

J Dancey

(20') The use of pharmacogenomics to improve cancer therapeutics
Canada Research Chair in Pharmacogenomics, Laval University

C. Guillemette,

(20') NCIC CTG: Drug Development Fellowship Report

I Gauthier,
Ottawa Hospital Research Institute

4:00 p.m. **New / Planned Studies, Report from Closed IND meeting, & IND executive** EE/LS/GB

4:25 p.m. Thank-you to Gerry Batist!

4:30 p.m. **Adjourn**